Nektar Therapeutics (NKTR) Other Non-Current Assets (2010 - 2026)

Nektar Therapeutics' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $11.2 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 108.44% year-over-year to $11.2 million in Q1 2026; TTM through Mar 2026 was $11.2 million, a 108.44% increase from a year earlier, with the FY2025 full-year figure at $14.1 million, up 204.28% from the prior year.
• Other Non-Current Assets fell to $11.2 million in Q1 2026 per NKTR's latest filing, from $14.1 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $33.1 million in Q3 2024 and bottomed at $1.4 million in Q1 2023.
• The 5-year median for Other Non-Current Assets is $4.6 million (2023), against an average of $6.4 million.
• Across the five-year window, Other Non-Current Assets soared 630.78% in 2024 and tumbled 84.4% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $2.2 million in 2022, then surged by 106.86% to $4.6 million in 2023, then gained by 0.06% to $4.6 million in 2024, then soared by 204.28% to $14.1 million in 2025, then decreased by 20.53% to $11.2 million in 2026.
• Per Business Quant, the three latest NKTR Other Non-Current Assets figures stand at $11.2 million (Q1 2026), $14.1 million (Q4 2025), and $5.2 million (Q3 2025).